Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-16, Stock:NVS, The news for the past five days is as follows:
2018-04-09: NEWS1: Cramer: There's always a better time to sell.NEWS2: Cramer: We got too negative on Friday—there's always a be....NEWS3: How AstraZeneca’s 1Q18 Shook Out.NEWS4: AveXis Inc Stock Skyrockets on Novartis Deal.NEWS5: AveXis Inc Stock Skyrockets on Novartis Deal.NEWS6: What Happened in the Stock Market Today.NEWS7: What Happened in the Stock Market Today.NEWS8: What Happened in the Stock Market Today.NEWS9: Wall Street Pares Gains Into Close as Trump Headlines Defy Easing Trade Fears.NEWS10: Wall Street Pares Gains Into Close as Trump Headlines Defy Easing Trade Fears.NEWS11: Stocks rise, but biggest gains fade as market stays volatile.NEWS12: Assessing the Performance of Novartis Stock in 1Q18.NEWS13: Health Care Sector Update for 04/09/2018: AVXS,NVS,IONS,AZN,MRK,MNLO.NEWS14: Health Care Sector Update for 04/09/2018: AVXS,NVS,IONS,AZN,MRK,MNLO.NEWS15: AveXis Pops 80% On Novartis Buyout As Celgene Rumored To Eye Others.NEWS16: Stocks Rise on Softer U.S. Approach in China Trade War.NEWS17: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher.NEWS18: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher.NEWS19: Dow Rises Sharply on Softer U.S. Approach in China Trade War; Tech Soars.NEWS20: Why AveXis, Inc. Stock Is Soaring Today.NEWS21: Why AveXis, Inc. Stock Is Soaring Today.NEWS22: Biotech Bears Get Squeezed.NEWS23: Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide.NEWS24: Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide.NEWS25: Analyst: AveXis M&A Could Support Interest In Regenxbio.NEWS26: Stocks soar, erasing last week's loss, as trade fears ease.NEWS27: Midday Update: Wall Street Rallies After White House Plays Down Trade War With China.NEWS28: Midday Update: Wall Street Rallies After White House Plays Down Trade War With China.NEWS29: Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis.NEWS30: Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis.NEWS31: Why AveXis, Inc. Stock Is Soaring Today.NEWS32: [$$] Why the Deal for AveXis Is a Powerful Vote for Replacement Gene Therapy.NEWS33: GSK’s Acquisition of Novartis’ Consumer Healthcare Joint Venture.NEWS34: AveXis Inc Stock Skyrockets on Novartis Deal.NEWS35: How a Rockville company benefits from Novartis&apos; $8.7B purchase of a Chicago biotech.NEWS36: Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis.NEWS37: Stocks rally as trade tensions keep investors guessing.NEWS38: Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For $8.7B.NEWS39: Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For $8.7B.NEWS40: Dow Jumps on Softer U.S. Approach in China Trade War; Tech Soars.NEWS41: Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis.NEWS42: AveXis Rockets 80% On Novartis Buyout As Other Biotechs Fly.NEWS43: Dow Pops on Softer U.S. Approach in China Trade War; Tech Is a Standout.NEWS44: Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'.NEWS45: [$$] Novartis's $9 Billion Bet Is Worth the Risk.NEWS46: Hedge Fund Adage Reaps Big Initial Gain on Health-Care Takeover.NEWS47: Rare Diseases Command Mega Prices With Novartis Wager on AveXis.NEWS48: Stocks turn higher; trade tensions keep investors guessing.NEWS49: Morning Movers: AveXis Soars on Novartis Takeover, Boeing Bounces, Leucadia Leaps.NEWS50: Wall Street Sees Rebound as Traders Assess US-China Trade Dispute.NEWS51: Wall Street Sees Rebound as Traders Assess US-China Trade Dispute.NEWS52: Stocks Rise Amid Indications U.S. Softens Approach in China Trade Battle.NEWS53: Stocks Rise: Facebook Lags; Amazon Jumps; Russia Stocks Rattled.NEWS54: Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space.NEWS55: Futures Up: Facebook Lags, Amazon Leads; Boeing Aces Airline Deal.NEWS56: Biogen faces increased 'pressure' after AveXis buyout by Novartis.NEWS57: The Swiss Stock Market Began The Trading Week With A Small Gain.NEWS58: The Swiss Stock Market Began The Trading Week With A Small Gain.NEWS59: European Markets Finished Little Changed After Early Gains Erode.NEWS60: European Markets Finished Little Changed After Early Gains Erode.NEWS61: Deutsche Bank, Novartis, AveXis, Facebook, Patrick Reed - 5 Things You Must Know.NEWS62: Swiss giant Novartis to buy US-based AveXis in $8.7B deal.NEWS63: Novartis buying AveXis for nearly $9 billion.NEWS64: Novartis bets big on gene therapy with $8.7 billion AveXis deal.NEWS65: Biotech Buyer Prays a Monster Premium Will Be Enough.NEWS66: Novartis to buy AveXis in $8.7bn gene-therapy deal.NEWS67: Novartis bets big on gene therapy with $8.7 billion AveXis deal.NEWS68: Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You’ve Never Heard Of.NEWS69: Novartis Acquires Gene Therapy Company for $8.7B.NEWS70: AveXis Inc. (AVXS) Has Soared To A New High After Bought By Novartis.NEWS71: AveXis Inc. (AVXS) Has Soared To A New High After Bought By Novartis.NEWS72: [$$] Novartis buys US gene therapy group AveXis for $8.7bn.NEWS73: Novartis Agrees to Buy AveXis in $8.7 Billion Deal.NEWS74: Novartis bets big on gene therapy with $8.7 bln AveXis deal.NEWS75: Correct: Novartis to acquire AveXis for $8.7 billion in cash.NEWS76: Novartis to Pay $8.7 Billion for AveXis.NEWS77: Novartis to Pay $8.7 Billion for AveXis.NEWS78: European Shares Broadly Higher As Markets Shrug Off Tariff Worries.NEWS79: European Shares Broadly Higher As Markets Shrug Off Tariff Worries.NEWS80: [$$] Novartis to Buy Gene Therapy Company AveXis for $8.7 Billion.NEWS81: [$$] Novartis to buy AveXis for $8.7bn.NEWS82: Novartis shells out $8.7 billion to buy AveXis.NEWS83: Novartis to acquire AxeXis for $8.7 billion in cash.NEWS84: Novartis AG to buy AveXis Inc for $8.7 billion.NEWS85: Novartis AG to buy AveXis Inc for $8.7 billion.NEWS86: Novartis CEO Spurs Rare-Disease Shift With $8.7 Billion Deal.NEWS87: Novartis to Buy AveXis in $8.7 Billion Gene-Therapy Deal.NEWS88: Novartis To Purchase AveXis For $8.7 Bln Cash - Quick Facts.NEWS89: Novartis To Purchase AveXis For $8.7 Bln Cash - Quick Facts.
2018-04-10: NEWS1: SPPI Shines On NSCLC Data, TNDM Sales Up 42%, TORC Breathes Easy, VRAY Abuzz.NEWS2: SPPI Shines On NSCLC Data, TNDM Sales Up 42%, TORC Breathes Easy, VRAY Abuzz.NEWS3: How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal.NEWS4: Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success?.NEWS5: Novartis' Acquisition of AveXis Takes Aim at Biogen.NEWS6: Novartis' Acquisition of AveXis Takes Aim at Biogen.NEWS7: Novartis&apos; Acquisition of AveXis Takes Aim at Biogen.NEWS8: Agios Pharmaceuticals Shares Rise on Buyout Speculation.NEWS9: Agios Pharmaceuticals Shares Rise on Buyout Speculation.NEWS10: Company News For Apr 10, 2018.NEWS11: Company News For Apr 10, 2018.NEWS12: Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide.NEWS13: Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide.NEWS14: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher.NEWS15: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher.NEWS16: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS17: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS18: Company News For Apr 10, 2018.NEWS19: Novartis' Acquisition of Avexis: Bad News for Biogen?.NEWS20: Novartis' Acquisition of Avexis: Bad News for Biogen?.NEWS21: Today’s Research Reports on Stocks to Watch: AveXis and Novartis.NEWS22: The Swiss Stock Market Climbed As Trade Anxiety Continues To Ease.NEWS23: The Swiss Stock Market Climbed As Trade Anxiety Continues To Ease.NEWS24: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS25: Focus: Lonza's virus factory shows gene therapy's Texas-sized promise.NEWS26: Novartis&apos; Acquisition of Avexis: Bad News for Biogen?.NEWS27: Novartis AG -- Moody's: $8.7 billion acquisition of AveXis strengthens Novartis's pipeline in gene therapy, but reduces financial flexibility.NEWS28: [$$] Novartis Bets $8.7 Billion on Gene-Therapy Company.NEWS29: Asian stocks mostly rise as investors weigh trade war fears.NEWS30: Asian stocks mostly rise as investors weigh trade war fears.
2018-04-11: NEWS1: Novartis’s Valuation and Analysts’ Recommendations on April 11.NEWS2: Incyte Expected to Report Robust Revenue Growth in Fiscal 2018.NEWS3: Novartis’s Stock Performance following the AveXis Agreement.NEWS4: This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous.NEWS5: This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous.NEWS6: Novartis Enters Agreement to Acquire AveXis.NEWS7: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS8: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS9: Alexion's Deal Discipline Sure Beats a Previous Disaster.NEWS10: This Little-Known Company Should Have Gilead&apos;s and Celgene&apos;s Investors Nervous.NEWS11: Why CASI Pharmaceuticals Stock Rose Last Week.NEWS12: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS13: The Swiss Stock Market Dropped On Syria Concerns.NEWS14: The Swiss Stock Market Dropped On Syria Concerns.
2018-04-12: NEWS1: Why One Drug Flop Tanked Incyte's Stock.NEWS2: Why One Drug Flop Tanked Incyte's Stock.NEWS3: Why One Drug Flop Tanked Incyte&apos;s Stock.NEWS4: GlaxoSmithKline Buys Novartis’s Stake in Joint Venture.NEWS5: The Swiss Stock Market Climbed As Syria Concerns Ease.NEWS6: The Swiss Stock Market Climbed As Syria Concerns Ease.NEWS7: Incyte Has Diversified Its Revenues across Multiple Product Lines.
2018-04-13: NEWS1: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS2: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS3: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV&apos;s Drugs Succeed in Phase III.NEWS4: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS5: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS6: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS7: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS8: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS9: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS10: Rigel Pharmaceuticals&apos; (RIGL) Stock Gains 16%: Here&apos;s Why.NEWS11: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS12: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS13: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS14: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS15: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS16: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS17: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS18: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS19: These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years.NEWS20: Same as the old boss — Novan makes interim CEO permanent.NEWS21: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.

Answer: Rise